部份中文马沙骨化醇处方资料（仅供参考）
商品名：Oxarol
英文名：Maxacalcitol
中文名：马沙骨化醇乳液
生产商：中外药制
药品介绍：
Oxarol（Maxacalcitol オキサロールローション。中文名：马沙骨化醇） 是日本中外制药公司开发的新型第三代活性维生素D类药物。其马沙骨化醇软膏/乳液于2000年上市，商品名为Oxarol软膏/乳液，用于治疗银屑病等干癣类皮肤病。注射液于2000年上市，商品名为Oxarol，用于治疗肾透析（肾衰）患者的继发性甲状旁腺功能亢进症(SHPT)。本品剂量很小，2.5~5.0微克/支，3次/周，肾透析（肾衰）患者一年用量不到1毫克。
オキサロール軟膏25μg／g/オキサロールローション25μg／g
药用类别名称
寻常型银屑病治疗剂
批准日期：2006年6月
商標名
Oxarol Ointment
Oxarol Lotion
一般名
マキサカルシトール（Maxacalcitol）（JAN）
慣用名
22‐oxacalcitriol
1α, 25‐dihydroxy‐22-oxavitamin D3
化学名
(＋)‐(5Z, 7E)‐(1S, 3R, 20S)‐20‐(3‐Hydroxy‐3‐methylbutyloxy)‐9, 10‐secopregna‐5, 7, 10(19)‐triene‐1, 3‐diol
構造式
分子式
C26H42O4
分子量
418.61
性　状
它是一种白色结晶性粉末。
很容易溶于甲醇, 易溶于乙醇(99.5), 微溶于乙醚, 不易溶于水。
药用药理学
1. 表皮角质形成细胞生长抑制作用
马克沙利醇抑制人表皮角质形成细胞(体外)的增殖。 此外, 在器官培养系统中, 利用寻常型银屑病患者的皮肤, 抑制表皮角质形成细胞的增殖, 以改善表皮增厚。此外, 为减少寻常型银屑病患者表皮DNA 合成和核裂变, 建议抑制细胞增殖异常过度生长。
2. 诱导分化为表皮角质形成细胞
甲氧氯醇是促进英博林 mRNA 表达的一种分化标志物 (体外)。另外, 寻常型银屑病患者的外部, 诱导洛里林的表达是表皮细胞分化标志物, 增加分化角蛋白的表达大于刺层。
3. 细胞因子、淋巴细胞等的影响。
通过刺激浓度依赖性抑制, 对人表皮角质形成细胞il-6的il-1 α分泌, 脾脏细胞淋巴细胞增殖刺激了琥珀酸-konkanavalin a浓度依赖性小鼠的增殖, 并对其进行了抑制 (体外)。 此外, 减少炎症细胞的浸润, 如多核细胞白细胞和T淋巴细胞, 由外部为患者的寻常型银屑病。
4. 关于作用机制的研究
Ma草利托力对人表皮角质形成细胞的维生素D受体有亲和力(体外)。另外, 与人维生素D结合蛋白的亲和力低于钙调尿素三醇, 观察到在表皮角质形成细胞细胞核(体外) 迁移较多。
适应症
寻常性干癣、鱼鳞癣群、掌跖角化症、掌跖脓疱症
用法与用量
通常每天对受影响的区域摩擦适当的量两次。另外, 减少适当的症状的次数。
包装
药膏: 10g/1
药膏: 10g/10
乳液: 10g/1
乳液: 10g/10
制造和销售
中外药制
注：以上中文不够完整，使用者以原处方资料为准。
完整说明附件：http://www.info.pmda.go.jp/go/pack/2691702M1036_1_10/ 
Psoriasis Vulgaris Treatment Ethical Drug Topical Lotion Containing Active Vitamin D3 Launch of "Oxarol® Lotion"
Chugai Pharmaceutical Co.Ltd.[Head Office, Chuo-ku, Tokyo; President, Osamu Nagayama] (hereafter, "Chugai")and Maruho Co.Ltd.[Head Office, Kita-ku, Osaka; President, Koichi Takagi](hereafter, "Maruho")are pleased to announce the market launch of "Oxarol® Lotion" (nonproprietary name, maxacalcitol; hereafter, "Lotion"), a treatment for keratosis including psoriasis vulgaris, scheduled on June.
The marketing approval for the product, which will be distributed by Maruho, was granted to Chugai on March.
As with the keratosis treatment "Oxarol® Ointment"(nonproprietary name, maxacalcitol; hereafter, "Ointment")for which marketing approval was also granted to Chugai, "Lotion" contains the active vitamin D3 derivative maxacalcitol as an active ingredient.With the modified new formulation for enhanced patient convenience, "Lotion" is easy to apply to common sites of psoriasis vulgaris including hairy areas such as head. "Lotion" containing active vitamin D3 will be a useful new topical treatment option.
1. About Maxacalcitol
Maxacalcitol, an active vitamin D3 derivative developed by Chugai, inhibits proliferation and induces differentiation of epidermal keratinocytes.  Since market launch of "Ointment" containing the active ingredient maxacalcitol in October 2001, it has been widely used in patients with keratosis including psoriasis vulgaris, remarkably improving the symptoms.
2. Features of "Oxarol®Lotion"
"Lotion" is an emulsion lotion that can be easily applied to hairy areas such as head and has excellent usability.  "Lotion" has shown to be highly effective and safe as with "Ointment" in the controlled clinical study in patients with psoriasis vulgaris.
Dermal transfer of "Lotion" in human skin has shown to be equivalence to that of "Ointment".  "Lotion" with excellent usability and efficacy/safety comparable to "Ointment” will be a useful new topical treatment option for psoriasis vulgaris.
The most frequently observed adverse drug reactions in the clinical study were 4 events of skin irritation(4.7%), 3 events of skin exfoliation(3.5%), and 2 events each of eczema and erythema (2.3%).
[Reference]
Product Summary
[Product Name]Oxarol®Lotion
[Nonproprietary Name]Maxacalcitol
[Composition]One gram of Oxarol® Lotion contains maxacalcitol 25μg.
[Indications]Psoriasis vulgaris, ichthyosis, palmoplantar keratosis
[Dosage and Administration]Appropriate amount of Oxarol®Lotion should be applied to the affected area twice daily. Depending on the symptom, application frequency should be decreased as necessary.
[Precaution concerning Dosage and Administration]The maximum recommended daily dose of maxacalcitol is 250 μg, or 10g of topical maxacalcitol.
[Package]Bottle; 10gx1, 10gx10
[Manufacturer]Chugai Pharmaceutical Co.Ltd.
[Release Date]June 18, 2007
[Date of Approval]March 15, 2007